Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study

BackgroundAmong persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time.MethodsWe recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age = 45.2 years [SD = 8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence.ResultsDepressive symptomatology was not significantly related to neuropsychological change (p’s > .05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r’s = .52–60; p’s < .05).ConclusionsAmong OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD.Trial registrationNCT01108679. Registered 21 April 2010.

• Publication year

  2017

• Venue

  Substance Abuse Treatment, Prevention, and Policy

• Publication date

  2017-11-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1186/s13011-017-0133-2PMID 29141650PMCID 5688712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of buprenorphine on psychomotor functions in patients on buprenorphine maintenance.

  2018cited by this paper
• Depression in the U.S. household population, 2009-2012.

  2014cited by this paper
• Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses.

  2014cited by this paper
• Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis.

  2012cited by this paper
• Factors affecting cognitive function of opiate-dependent patients.

  2012influential reference
• Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices

  2012cited by this paper
• Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change

  2011cited by this paper
• Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

  2007cited by this paper
• Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies.

  2006cited by this paper
• Methadone maintenance improves cognitive performance after two months of treatment.

  2006influential reference
• Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management

  2006cited by this paper
• Short-term neuropsychological recovery in clients with substance use disorders.

  2005cited by this paper
• Statistical Power Analysis: A Simple and General Model for Traditional and Modern Hypothesis Tests, Second Ediction

  2004cited by this paper
• Clinical Implications and Methodological Challenges in the Study of the Neuropsychological Correlates of Cannabis, Stimulant, and Opioid Abuse

  2004cited by this paper
• Demographic Effects and Use of Demographically Corrected Norms with the WAIS-III and WMS-III

  2003cited by this paper
• The 50 and 100-Item Short Forms of the Paced Auditory Serial Addition Task (PASAT): Demographically Corrected Norms and Comparisons with the Full PASAT in Normal and Clinical Samples

  2003cited by this paper
• Self-report and objective measures of cognitive deficit in patients entering substance abuse treatment.

  1999cited by this paper
• Hopkins Verbal Learning Test—Revised: Normative data and analysis of inter-form and test–retest reliability.

  1998cited by this paper
• Neuropsychological performance of recently abstinent alcoholics and cocaine abusers.

  1995cited by this paper
• The Fifth Edition of the Addiction Severity Index.

  1992cited by this paper
• Bmc Clinical Pharmacology Methadone vs. Buprenorphine/naloxone during Early Opioid Substitution Treatment: a Naturalistic Comparison of Cognitive Performance Relative to Healthy Controls

  year unknowncited by this paper

• Self-Reported Cognitive Impairments in Office-Based Treatment for Opioid Use Disorder with Buprenorphine or Extended-Release Naltrexone

  2025cites this paper
• Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder – a longitudinal structural magnetic resonance imaging study

  2024cites this paper
• Neurocognitive performance of patients undergoing intravenous versus oral opioid agonist treatment: a prospective multicenter study on three-month treatment effects

  2024cites this paper
• Social and cognitive determinants of medications for opioid use disorder outcomes: A systematic review using a social determinants of health framework

  2024cites this paper
• Gender disparities in neuropsychological assessment research in drug abuse populations: A systematic review

  2024cites this paper
• Relationship of neurocognition and treatment retention in subjects on opioid agonist treatment

  2022cites this paper
• Buprenorphine reverses neurocognitive impairment in EcoHIV infected mice: A potential therapy for HIV-NCI

  2022cites this paper
• Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment.

  2021cites this paper
• "HIV and Aging in Special Populations: From the Mitochondria to the Metropolis"-Proceedings From the 2019 Conference.

  2021cites this paper
• Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment

  2020cites this paper
• Recovery From Opioid Problems in the US Population: Prevalence, Pathways, and Psychological Well-Being.

  2020cites this paper
• The Effects of Opioids on HIV Neuropathogenesis

  2019cites this paper
• The Impact of Substance Abuse on HIV-Mediated Neuropathogenesis in the Current ART Era.

  2019cites this paper
• Neurologic, Cognitive, and Behavioral Consequences of Opioid Overdose: a Review

  2019cites this paper
• Endogenous Opiates and Behavior: 2017.

  2019cites this paper
• Neuropsychological changes in patients with substance use disorder after completion of a one month intensive outpatient treatment program

  2018cites this paper